Shares of Pharming Group N.V. (PHAR) surged 9.51% in pre-market trading on Thursday following the company's announcement of better-than-expected second-quarter results and raised full-year guidance. The biotech firm, which specializes in rare disease treatments, reported significant growth in its commercial portfolio and pipeline advancements.

Pharming's second-quarter earnings per share came in at $0.06, considerably outperforming the analyst consensus estimate of -$0.03. This marks a substantial improvement from the $0.00 reported in the same quarter last year. Total revenues for the quarter reached $93.2 million, up 25.8% year-over-year and exceeding analyst expectations of $82.63 million. The company's flagship product, RUCONEST, saw a 28% increase in revenue to $80.4 million, while Joenja revenue grew 15% to $12.8 million.

Buoyed by the strong performance, Pharming raised its full-year 2025 revenue guidance to a range of $335 million to $350 million, up from the previous guidance of $325 million to $340 million. The company also reported progress in its pipeline, including advancements in leniolisib for additional primary immunodeficiencies and KL1333 for mitochondrial diseases. CEO Fabrice Chouraqui expressed confidence in the company's long-term strategy, citing the strength of their commercial portfolio and advancing pipeline targeting significant, underserved markets.